[ad_1] Generic drugmaker Dr. Reddy’s Laboratories has received establishment inspection report (EIR) for its Srikakulam formulations manufacturing facility from the U.S. Food and Drug Administration (U.S. FDA) with a voluntary action indicated (VAI) classification. Following a good manufacturing practice (GMP) and a pre-approval inspection (PAI) in July, the facility (FTO 11) received seven observations from […]
Continue Reading
[ad_1] Generic drugmaker Dr. Reddy’s Laboratories’ consolidated net profit for the June quarter increased marginally to ₹1,409.9 crore from Rs.1,392.4 crore year earlier as revenue from the all important U.S. market declined amid increased price erosion in certain key products. The net profit came on a more than 11% increase in total revenue from operations […]
Continue Reading
[ad_1] Representational image only. | Photo Credit: Special Arrangement Pharma major Dr. Reddy’s Laboratories is acquiring the U.S. generic prescription product portfolio of Australia’s Mayne Pharma Group for an upfront cash consideration of around $90 million. The portfolio includes 45 commercial products, four pipeline products and 40 approved non-marketed products, including generic products focussed on […]
Continue Reading
[ad_1] As part of the settlement, the underlying litigation will be dismissed, the Hyderabad-headquartered drugmaker said. As part of the settlement, the underlying litigation will be dismissed, the Hyderabad-headquartered drugmaker said. Pharma major Dr. Reddy’s Laboratories has entered into settlement agreement with British drugmaker Indivior resolving patent litigation relating to latter’s opioid dependence treatment drug […]
Continue Reading